Literature DB >> 12503822

Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors.

D Strumberg1, D Voliotis, J G Moeller, R A Hilger, H Richly, S Kredtke, C Beling, M E Scheulen, S Seeber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12503822     DOI： 10.5414/cpp40580

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN： 0946-1965            Impact factor:   1.366


× No keyword cloud information.
  23 in total

1.  Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma.

Authors:  L B Nabors; J G Supko; M Rosenfeld; M Chamberlain; S Phuphanich; T Batchelor; S Desideri; X Ye; J Wright; S Gujar; S A Grossman
Journal:  Neuro Oncol       Date:  2011-09-27       Impact factor: 12.300

Review 2.  Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.

Authors:  Apurva A Desai; Walter M Stadler
Journal:  Curr Oncol Rep       Date:  2005-03       Impact factor: 5.075

Review 3.  From laptop to benchtop to bedside: structure-based drug design on protein targets.

Authors:  Lu Chen; John K Morrow; Hoang T Tran; Sharangdhar S Phatak; Lei Du-Cuny; Shuxing Zhang
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

4.  Not the comfy chair! Cancer drugs that act against multiple active sites.

Authors:  Laurence Booth; Andrew Poklepovic; Paul Dent
Journal:  Expert Opin Ther Targets       Date:  2019-11-14       Impact factor: 6.902

5.  Exon 15 BRAF mutations are uncommon in canine oral malignant melanomas.

Authors:  Suzanne Shelly; May B Chien; Becky Yip; Michael S Kent; Alain P Theon; Jennifer L McCallan; Cheryl A London
Journal:  Mamm Genome       Date:  2005-03       Impact factor: 2.957

Review 6.  Melanoma genetics and the development of rational therapeutics.

Authors:  Yakov Chudnovsky; Paul A Khavari; Amy E Adams
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

7.  A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors.

Authors:  David R D'Adamo; Mark A Dickson; Mary L Keohan; Richard D Carvajal; Martee L Hensley; Catherine M Hirst; Marietta O Ezeoke; Linda Ahn; Li-Xuan Qin; Cristina R Antonescu; Robert A Lefkowitz; Robert G Maki; Gary K Schwartz; William D Tap
Journal:  Oncologist       Date:  2018-08-20

8.  Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis.

Authors:  Oliver Crespo; Stacey C Kang; Richard Daneman; Tamsin M Lindstrom; Peggy P Ho; Raymond A Sobel; Lawrence Steinman; William H Robinson
Journal:  J Clin Immunol       Date:  2011-08-17       Impact factor: 8.317

9.  Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma.

Authors:  Khaldoun Almhanna; Philip A Philip
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

10.  Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.

Authors:  Sung Hee Hwang; Aaron T Wecksler; Guodong Zhang; Christophe Morisseau; Long V Nguyen; Samuel H Fu; Bruce D Hammock
Journal:  Bioorg Med Chem Lett       Date:  2013-05-15       Impact factor: 2.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.